Quintiles Transnational (www.quintiles.com) and dgd Research (www.dgdresearch.com) will provide analytical and clinical services for Akesis Pharmaceuticals’ lead candidate, AKP-020, or BEOV. AKP-020 has shown considerable potential as a treatment for type 2 diabetes, according to Akesis.
Quintiles will be responsible for overall project supervision and data management of upcoming trials. dgd Research will conduct the planned Phase Ib study in its San Antonio facility.
